<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in children: General principles</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in children: General principles</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in children: General principles</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ruth A McDonald, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5913719"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Once the estimated glomerular filtration rate declines to less than 30 mL/min per 1.73 m<sup>2</sup> and the child is in stage 4 chronic kidney disease, it is time to start preparing the child and the family/caregiver for renal replacement therapy [<a href="#rid1">1</a>]. Although there have been many advances in conservative kidney replacement therapy, kidney transplantation is the best treatment for children with end-stage kidney disease (ESKD). Kidney allograft and patient survival have increased due to improvements in the care of young patients and advances in immunosuppressive therapy, thereby resulting in reduced frequency and severity of acute rejection. (See  <a class="medical medical_review" href="/d/html/16179.html" rel="external">"Overview of kidney replacement therapy for children with chronic kidney disease", section on 'Preemptive transplantation as preferred kidney replacement therapy modality'</a> and  <a class="medical medical_review" href="/d/html/6128.html" rel="external">"Kidney transplantation in children: Immunosuppression"</a>.)</p><p>This topic will provide an overview of aspects that should be considered in children prior to transplantation. Induction and maintenance immunosuppressive therapy, complications, and outcome of kidney transplantation in children are presented separately. (See  <a class="medical medical_review" href="/d/html/6128.html" rel="external">"Kidney transplantation in children: Immunosuppression"</a> and  <a class="medical medical_review" href="/d/html/6143.html" rel="external">"Kidney transplantation in children: Complications"</a> and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes"</a>.)</p><p class="headingAnchor" id="H5913726"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In the United States, approximately 800 kidney transplants are performed in children below 18 years of age annually [<a href="#rid2">2</a>].</p><p>In the United States, the deceased donor kidney allocation policy was revised and the new United States <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fmedia%2F1200%2Foptn_policies.pdf&amp;token=jgNBVRq5heGSKJUMvIxSckAi3J85133j51zxpREEp3KKILn8mtTakYhAmibr55MPryZsqMyHOv%2BLy0bPcs0%2Fkb%2BXfgKuJi9a6rqmoHllWDM%3D&amp;TOPIC_ID=6120" target="_blank">Kidney Allocation System</a> went into effect in December 2014 (see  <a class="medical medical_review" href="/d/html/7337.html" rel="external">"Kidney transplantation in adults: Organ sharing"</a>). An analysis of data 12 months after implementation showed that transplants for pediatric patients (aged 0 to 17) declined slightly from 4.2 to 3.9 percent [<a href="#rid3">3</a>]. However, pediatric candidates continue to receive priority that provides them greater access to more timely transplants and kidneys that are expected to function longer than in adult candidates. Limited data showed no difference in patient survival but less graft loss under the new system two years after implementation of the Kidney Allocation System [<a href="#rid4">4</a>]. Other countries have also implemented policy changes to prioritize allocation of allografts from deceased donors to pediatric recipients. As an example, such a policy has been in place in France since 1995.</p><p>Data from the North American Pediatric Renal Trials and Collaborate Studies (NAPRTCS) registry from 1987 to 2017 provide information regarding recipient characteristics [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Sex – More male children (approximately 60 percent) receive kidney transplants compared with females, primarily due to the higher numbers of males with congenital anomalies of the kidney and urinary tract (CAKUT) that progress to end-stage kidney disease (ESKD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ethnicity – The ethnicity of pediatric recipients has changed over the years, with a decrease in the percentage of White recipients, from a high of 72 percent in 1987 to approximately 50 percent in 2017.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying primary disease – In the NAPRTCS registry, the most common primary diagnoses occurring in approximately 30 percent of pediatric recipients are due to CAKUT, which include renal aplasia/hypoplasia/dysplasia and obstructive uropathy. Other underlying etiologies include hereditary kidney diseases (eg, polycystic kidney disease, nephronophthisis, cystinosis, congenital nephrotic syndrome, oxalosis, hereditary nephritis, atypical hemolytic uremic syndrome, and Drash syndrome), acquired glomerular disease (eg, focal segmental glomerulosclerosis and secondary glomerulonephritis such as lupus nephritis), reflux nephropathy and pyelo-/interstitial nephritis, and hemolytic uremic syndrome. (See  <a class="medical medical_review" href="/d/html/6115.html" rel="external">"Chronic kidney disease in children: Definition, epidemiology, etiology, and course", section on 'Etiology'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ethnicity – There is some variation in the prevalence of the underlying etiology of pediatric kidney recipients. In Black children, focal segmental glomerulosclerosis is the most common cause of ESKD, whereas CAKUT is the most common etiology in White and Hispanic recipients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Age – Etiology also varies with age [<a href="#rid5">5,6</a>]. For example, CAKUT is the primary cause of ESKD in 40 percent of children less than six years of age, whereas it is the etiology in only 20 percent of those between 11 and 17 years of age.</p><p></p><p class="headingAnchor" id="H17417151"><span class="h1">ADVANTAGES OF KIDNEY TRANSPLANTATION</span><span class="headingEndMark"> — </span>Kidney transplantation is the preferred kidney replacement therapy for children with end-stage kidney disease (ESKD) as patient survival and quality of life are superior for children undergoing transplantation compared with those who remain on dialysis [<a href="#rid7">7,8</a>]. In addition, young children (below six years of age) are more likely to have improved growth after transplantation compared with those undergoing either chronic hemodialysis or peritoneal dialysis [<a href="#rid9">9</a>]. (See  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Patient survival'</a> and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Growth after kidney transplantation'</a>.)</p><p class="headingAnchor" id="H17417513"><span class="h1">PREEMPTIVE TRANSPLANTATION</span><span class="headingEndMark"> — </span>Children frequently undergo <strong>primary or preemptive</strong> transplantation, in which transplantation is the first mode of treatment for end-stage kidney disease (ESKD). Preemptive transplants occur more frequently in children than in adults because of the parents'/caregivers' and patients' desire to avoid dialysis when a living donor is available [<a href="#rid10">10</a>]. When performed, this procedure most commonly involves a living donor who is related to the recipient. Children can also be listed for a preemptive deceased donor transplant. Based on the available data, we recommend preemptive kidney transplantation if none of the following contraindications are present and there is a readily available living donor. If there is not an available living donor, we place the child on the active deceased donor waitlist in the chance that they may receive a preemptive transplant before needing dialysis.</p><p>Preemptive transplants cannot be performed or are not recommended in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>Need for pretransplant nephrectomies (ie, malignant renovascular hypertension, chronic pyelonephritis, or nephrotic syndrome with the associated complications due to hypercoagulability)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ESKD from autoimmune disease with persistently high titers of autoantibody (ie, antiglomerular basement membrane disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ongoing active infections</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Underlying kidney disease is still active and associated with rapidly progressive disease (ie, hemolytic uremic syndrome or crescentic glomerulonephritis)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the patient or caregivers are not yet able to cope with the regimented care necessary for the transplant recipient as exhibited by nonadherence to their CKD care</p><p></p><p>Data from the North American Pediatric Renal Trials and Collaborate Studies (NAPRTCS) registry and a study from a single tertiary center reported improved allograft and/or patient survival with preemptive transplantation compared with transplantation while undergoing dialysis in patients with primary kidney transplants [<a href="#rid11">11,12</a>]. Other studies have found that allograft and patient survival and the incidence of rejection were similar in patients transplanted preemptively versus those transplanted while already undergoing dialysis [<a href="#rid13">13-15</a>].</p><p class="headingAnchor" id="H5913733"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>There are contraindications to kidney transplantation in children, which include:</p><p class="bulletIndent1"><span class="glyph">●</span>Uncontrolled extrarenal malignancies</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic sepsis</p><p class="bulletIndent1"><span class="glyph">●</span>Severe irreversible multisystem organ system failure not correctable by organ transplant</p><p class="bulletIndent1"><span class="glyph">●</span>Severe cardiac or pulmonary dysfunction in a patient who is not a candidate for multiorgan transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Life-threatening disorder of extrarenal origin that is not correctable by organ transplant</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated levels of circulating antiglomerular basement membrane antibodies (see  <a class="medical medical_review" href="/d/html/3085.html" rel="external">"Anti-GBM (Goodpasture) disease: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/d/html/7345.html" rel="external">"Anti-GBM (Goodpasture) disease: Recurrence after transplantation"</a>)</p><p></p><p>Previously, ABO incompatibility and the presence of cytotoxic antilymphocyte antibodies against the donor were contraindications to transplantation; however, subsequent advances with specific protocols have permitted such transplantation in some centers [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation"</a>.)</p><p>Human immunodeficiency virus (HIV) infection was traditionally considered an absolute contraindication for transplantation. However, improvements in the long-term prognosis of those with HIV infection have prompted many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. (See  <a class="medical medical_review" href="/d/html/7332.html" rel="external">"Kidney transplantation in adults: Kidney transplantation in patients with HIV"</a>.)</p><p class="headingAnchor" id="H3462511731"><span class="h1">DELAYED TRANSPLANTATION</span><span class="headingEndMark"> — </span>Kidney transplantation should be delayed for several months in those with ongoing active infections or if the disease responsible for kidney failure is active and associated with rapidly progressive disease (eg, hemolytic uremic syndrome or crescentic glomerulonephritis). Transplantation should only be performed when there has been successful treatment of these conditions so they do not negatively affect the allograft. Patients with hepatitis B or C infection should not be excluded unless they have active liver disease. (See  <a class="medical medical_review" href="/d/html/7309.html" rel="external">"Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient"</a>.)</p><p class="headingAnchor" id="H5913747"><span class="h1">DONOR CHOICE</span><span class="headingEndMark"> — </span>The results of kidney transplantation with a living donor are superior to those with a deceased donor [<a href="#rid6">6,8</a>]. A multivariate analysis of United Network for Organ Sharing data showed that even recipients of kidneys from older living donors had a significant long-term allograft survival advantage over those who received a kidney from a young deceased donor [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes", section on 'Donor source and age'</a>.)</p><p>Advantages associated with living donor kidney transplantation include:</p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of delayed allograft function is lower.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term allograft survival is higher.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dialysis can be avoided or the period on dialysis can be shortened because the time of transplantation is decided in advance. This may limit dialysis-related complications, such as growth impairment.</p><p></p><p>Despite these advantages, the proportion of living donors varies greatly among countries and regions [<a href="#rid18">18</a>]. Several factors that may explain these differences include the activity level of deceased donor transplant programs in the region or country, cultural variations, and the manner in which parents are solicited for donation.</p><p>Living donors should be informed of potential risks. Possible postoperative complications include abscess and hematoma. The incidence of mortality is low for donors. (See  <a class="medical medical_review" href="/d/html/7315.html" rel="external">"Kidney transplantation in adults: Evaluation of the living kidney donor candidate"</a>.)</p><p>Despite the general desirability of living donor allografts, a deceased donor may be preferred in settings in which there is a high risk of recurrent disease leading to loss of the allograft, as with rapidly progressive focal glomerulosclerosis. Support for this exception is provided by the finding that long-term survival of living and deceased donor allografts is similar among children with focal glomerulosclerosis [<a href="#rid19">19</a>]. The loss of benefit was associated with recurrent disease.</p><p class="headingAnchor" id="H5913754"><span class="h1">PRETRANSPLANT EVALUATION</span><span class="headingEndMark"> — </span>Prior to kidney transplantation, the recipient should undergo the following evaluation and preparation to reduce complications and increase allograft and patient survival.</p><p class="bulletIndent1"><span class="glyph">●</span>Detection of anti-human leukocyte antigen (HLA) antibodies to the donor</p><p class="bulletIndent1"><span class="glyph">●</span>Correction of any significant urinary tract abnormality</p><p class="bulletIndent1"><span class="glyph">●</span>Detection and treatment of any infection prior to transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Completion of routine childhood immunizations, including <a class="drug drug_pediatric" data-topicid="13006" href="/d/drug information/13006.html" rel="external">varicella vaccine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Review of whether nephrectomy would be beneficial long-term</p><p></p><p class="headingAnchor" id="H5913762"><span class="h2">Detection and consequences of sensitization</span><span class="headingEndMark"> — </span>The presence of preformed HLA antibodies are likely to result in severe antibody-mediated rejection and early allograft loss. Several different assays are available to determine the sensitivity (ie, presence of HLA antibodies) of a potential transplant recipient to donor HLA antigens. These assays typically test for the presence of HLA antibodies by testing the serum from the recipient to a panel of HLA antigens or lymphocytes from different donors. (See  <a class="medical medical_review" href="/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation", section on 'Approach to the sensitized transplant candidate'</a>.)</p><p>The final test of sensitization when a specific donor has been identified is the cross match, which screens for preformed anti-HLA antibodies that would injure the kidney from that specific donor. In the crossmatch, the recipient serum is incubated with the donor's lymphocytes in the presence of complement. (See  <a class="medical medical_review" href="/d/html/7351.html" rel="external">"Kidney transplantation in adults: HLA-incompatible transplantation", section on 'Approach to the sensitized transplant candidate'</a>.)</p><p class="headingAnchor" id="H5913769"><span class="h2">Urinary tract abnormalities</span><span class="headingEndMark"> — </span>The lower urinary tract should be evaluated using a voiding cystourethrogram to detect any abnormality that should be corrected prior to transplantation in patients with history of congenital abnormalities of the kidney and urinary tract (CAKUT) or infection [<a href="#rid20">20-22</a>]. Bladder and urethra abnormalities may be responsible for ureterohydronephrosis of the allograft, thereby increasing the risk of allograft loss. These and other abnormalities may increase the risk of urinary tract infection and, possibly, urosepsis.</p><p>Patients with high-grade vesicoureteric reflux or permanent urinary infection should undergo nephroureterectomy to avoid the development of urosepsis. Children with lower tract uropathies (posterior urethral valves, prune-belly syndrome, and neurogenic bladder) and abnormalities of bladder function should be assessed carefully with urodynamic studies. It may be necessary to enlarge the bladder with an intestinal segment in patients with a small pathologic bladder. (See  <a class="medical medical_review" href="/d/html/5002.html" rel="external">"Prune-belly syndrome"</a> and  <a class="medical medical_review" href="/d/html/6574.html" rel="external">"Management of posterior urethral valves"</a>.)</p><p class="headingAnchor" id="H5913776"><span class="h2">Infectious disease issues</span><span class="headingEndMark"> — </span>Steps to prevent infectious complications associated with kidney transplantation are essential. The urinary tract, skin, teeth, and sinuses should be carefully examined for signs of infection or site of chronic infection.</p><p>Routine childhood immunizations should be completed, if possible, prior to immunosuppression, particularly if attenuated live virus vaccines are used [<a href="#rid23">23</a>]. Live vaccines, such as varicella and measles, should be administered at least two months prior to transplantation. If vaccination is incomplete, further vaccination should be delayed three to six months after transplantation to maximize immunogenicity and live vaccines are generally contraindicated [<a href="#rid24">24</a>]. <a class="drug drug_pediatric" data-topicid="12940" href="/d/drug information/12940.html" rel="external">Inactivated influenza vaccine</a> can be administered as early as one month after transplantation. (See  <a class="medical medical_review" href="/d/html/3892.html" rel="external">"Immunizations in solid organ transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H5913783"><span class="h2">Native nephrectomy</span><span class="headingEndMark"> — </span>The need for native nephrectomy is controversial. Loss of residual excretory capacity and erythropoietin production are potential complications of native nephrectomy should the transplant fail.</p><p>However, in certain cases, native nephrectomy may be beneficial, although data are limited. These indications include intractable urinary tract infection, high-grade vesicoureteral reflux, severe refractory hypertension, significant polyuria, or persistent nephrosis [<a href="#rid25">25-27</a>]. Native nephrectomy also has been suggested for children with X-Y gonadal dysgenesis and kidney failure (Drash syndrome) as the frequency of Wilms tumor is high if the kidneys are left in place. In addition, native nephrectomy may reduce antihypertensive therapeutic measures [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/6137.html" rel="external">"Congenital nephrotic syndrome"</a>.)</p><p class="headingAnchor" id="H16551819"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/16440.html" rel="external">"Patient education: Kidney transplant (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/16442.html" rel="external">"Patient education: Planning for a kidney transplant (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5913790"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred treatment for end-stage kidney disease (ESKD) in children</strong> – Kidney transplantation is the treatment of choice for children with ESKD because of its superior patient survival rate compared with chronic dialysis. In addition, it is associated with better growth and developmental outcomes. (See <a class="local">'Advantages of kidney transplantation'</a> above and  <a class="medical medical_review" href="/d/html/6135.html" rel="external">"Kidney transplantation in children: Outcomes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Underlying etiology of ESKD</strong> – The most common cause of ESKD in children who undergo transplantation is congenital anomalies of the kidney and urinary tract (CAKUT; 30 percent), followed by hereditary/genetic kidney diseases and glomerular disorders, particularly focal glomerulosclerosis in Black patients. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preemptive transplantation</strong> – Preemptive transplantation refers to transplantation as the first mode of treatment for ESKD. In most cases, the graft is from a living donor who is related to the recipient. Although it remains uncertain whether preemptive kidney transplantation is associated with better long-term outcome compared with transplantation while undergoing dialysis, this is a common approach for children because of the parents'/caregivers' and patients' desire to avoid dialysis when a living donor is available.</p><p></p><p class="bulletIndent1">Our approach is to offer preemptive kidney transplantation to suitable transplant candidates if there is a readily available living donor. If there is not an available living donor, we place the patient on the active deceased donor waitlist in the chance that they may receive a transplant before needing dialysis. (See <a class="local">'Preemptive transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications for transplantation</strong> – There are few contraindications for kidney transplantation as the modality of choice for kidney replacement therapy in children with ESKD. These include sepsis, uncontrolled extrarenal malignancies, irreversible multiorgan failure, severe cardiac and pulmonary dysfunction not corrected by organ transplant, underlying life-threatening disorder not corrected by kidney transplant, elevated levels of antiglomerular basement membrane antibodies, and recent history of nonadherence to medical care. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed transplantation</strong> – Transplantation is delayed for children with active infections or if the underlying cause of ESKD is active and associated with rapidly progressive disease (eg, hemolytic uremic syndrome). Transplantation is performed when there has been successful treatment of these conditions. (See <a class="local">'Delayed transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor choice</strong> – Graft survival is typically superior with a living donor versus a deceased donor allograft. Despite the general desirability of living donor allografts, a deceased donor may be preferred in settings in which there is a high risk of recurrent disease leading to loss of the allograft, as with rapidly progressive focal glomerulosclerosis. (See <a class="local">'Donor choice'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pretransplant evaluation</strong> – Pretransplant evaluation and preparation are key components for a successful transplant in the pediatric recipient and include the following (see <a class="local">'Pretransplant evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Detection of anti-human leukocyte antigen (HLA) antibodies to the donor</p><p class="bulletIndent2"><span class="glyph">•</span>Correction of any significant urinary tract abnormality</p><p class="bulletIndent2"><span class="glyph">•</span>Detection and treatment of any infection prior to transplantation</p><p class="bulletIndent2"><span class="glyph">•</span>Completion of routine childhood immunizations</p><p class="bulletIndent2"><span class="glyph">•</span>Review of whether nephrectomy would be beneficial long term</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.</a></li><li><a class="nounderline abstract_t">Etesami K, Lestz R, Hogen R. Pediatric kidney transplantation in the United States. Curr Opin Organ Transplant 2020; 25:343.</a></li><li><a class="nounderline abstract_t">Stewart DE, Kucheryavaya AY, Klassen DK, et al. Changes in Deceased Donor Kidney Transplantation One Year After KAS Implementation. Am J Transplant 2016; 16:1834.</a></li><li><a class="nounderline abstract_t">Jackson KR, Zhou S, Ruck J, et al. Pediatric deceased donor kidney transplant outcomes under the Kidney Allocation System. Am J Transplant 2019; 19:3079.</a></li><li><a class="nounderline abstract_t">Chua A, Cramer C, Moudgil A, et al. Kidney transplant practice patterns and outcome benchmarks over 30 years: The 2018 report of the NAPRTCS. Pediatr Transplant 2019; 23:e13597.</a></li><li><a class="nounderline abstract_t">Matas AJ, Smith JM, Skeans MA, et al. OPTN/SRTR 2013 Annual Data Report: kidney. Am J Transplant 2015; 15 Suppl 2:1.</a></li><li><a class="nounderline abstract_t">McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.</a></li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies. 2014 Annual Report. Available at: http://www.naprtcs.org (Accessed on July 23, 2021).</li><li class="breakAll">North American Pediatric Renal Trials and Collaborative Studies. 2008 Annual Report. Available at: https://web.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf (Accessed on June 09, 2011).</li><li><a class="nounderline abstract_t">Neu AM. Special issues in pediatric kidney transplantation. Adv Chronic Kidney Dis 2006; 13:62.</a></li><li><a class="nounderline abstract_t">Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study. Transplantation 2000; 69:1414.</a></li><li><a class="nounderline abstract_t">Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13:1358.</a></li><li><a class="nounderline abstract_t">Flom LS, Reisman EM, Donovan JM, et al. Favorable experience with pre-emptive renal transplantation in children. Pediatr Nephrol 1992; 6:258.</a></li><li><a class="nounderline abstract_t">Nevins TE, Danielson G. Prior dialysis does not affect the outcome of pediatric renal transplantation. Pediatr Nephrol 1991; 5:211.</a></li><li><a class="nounderline abstract_t">Cransberg K, Smits JM, Offner G, et al. Kidney transplantation without prior dialysis in children: the Eurotransplant experience. Am J Transplant 2006; 6:1858.</a></li><li><a class="nounderline abstract_t">Shishido S, Hasegawa A. Current status of ABO-incompatible kidney transplantation in children. Pediatr Transplant 2005; 9:148.</a></li><li><a class="nounderline abstract_t">Dale-Shall AW, Smith JM, McBride MA, et al. The relationship of donor source and age on short- and long-term allograft survival in pediatric renal transplantation. Pediatr Transplant 2009; 13:711.</a></li><li><a class="nounderline abstract_t">Harambat J, van Stralen KJ, Schaefer F, et al. Disparities in policies, practices and rates of pediatric kidney transplantation in Europe. Am J Transplant 2013; 13:2066.</a></li><li><a class="nounderline abstract_t">Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59:328.</a></li><li><a class="nounderline abstract_t">Churchill BM, Jayanthi RV, McLorie GA, Khoury AE. Pediatric renal transplantation into the abnormal urinary tract. Pediatr Nephrol 1996; 10:113.</a></li><li><a class="nounderline abstract_t">Krieger JN, Stubenbord WT, Vaughan ED Jr. Transplantation in children with end stage renal disease of urologic origin. J Urol 1980; 124:508.</a></li><li><a class="nounderline abstract_t">Warshaw BL, Edelbrock HH, Ettenger RB, et al. Renal transplantation in children with obstructive uropathy. J Urol 1980; 123:737.</a></li><li><a class="nounderline abstract_t">Feldman AG, Beaty BL, Curtis D, et al. Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs. JAMA Pediatr 2019; 173:260.</a></li><li><a class="nounderline abstract_t">Fox TG, Nailescu C. Vaccinations in pediatric kidney transplant recipients. Pediatr Nephrol 2019; 34:579.</a></li><li><a class="nounderline abstract_t">Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.</a></li><li><a class="nounderline abstract_t">Ghane Sharbaf F, Bitzan M, Szymanski KM, et al. Native nephrectomy prior to pediatric kidney transplantation: biological and clinical aspects. Pediatr Nephrol 2012; 27:1179.</a></li><li><a class="nounderline abstract_t">Pickles C, Kaur A, Wallace D, et al. Bilateral native nephrectomies for severe hypertension in children with stage 5 chronic kidney disease leads to improved BP control following transplantation. Pediatr Nephrol 2020; 35:2373.</a></li><li><a class="nounderline abstract_t">Brubaker AL, Stoltz DJ, Chaudhuri A, et al. Superior Hypertension Management in Pediatric Kidney Transplant Patients After Native Nephrectomy. Transplantation 2018; 102:1172.</a></li></ol></div><div id="topicVersionRevision">Topic 6120 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11904577" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32692040" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pediatric kidney transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26932731" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Changes in Deceased Donor Kidney Transplantation One Year After KAS Implementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31062464" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pediatric deceased donor kidney transplant outcomes under the Kidney Allocation System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31657095" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Kidney transplant practice patterns and outcome benchmarks over 30 years: The 2018 report of the NAPRTCS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25626344" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : OPTN/SRTR 2013 Annual Data Report: kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215481" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Long-term survival of children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215481" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Long-term survival of children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15215481" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term survival of children with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412972" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Special issues in pediatric kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798764" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11961024" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Preemptive kidney transplantation: the advantage and the advantaged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1616835" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Favorable experience with pre-emptive renal transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031837" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prior dialysis does not affect the outcome of pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16771812" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Kidney transplantation without prior dialysis in children: the Eurotransplant experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15787785" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Current status of ABO-incompatible kidney transplantation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207226" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The relationship of donor source and age on short- and long-term allograft survival in pediatric renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23718940" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disparities in policies, practices and rates of pediatric kidney transplantation in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135087" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8611337" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pediatric renal transplantation into the abnormal urinary tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6999178" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Transplantation in children with end stage renal disease of urologic origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6999174" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Renal transplantation in children with obstructive uropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30640369" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29671067" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vaccinations in pediatric kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275969" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22366876" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Native nephrectomy prior to pediatric kidney transplantation: biological and clinical aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885281" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Bilateral native nephrectomies for severe hypertension in children with stage 5 chronic kidney disease leads to improved BP control following transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29953422" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Superior Hypertension Management in Pediatric Kidney Transplant Patients After Native Nephrectomy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
